AR053094A1 - Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina y composicion farmaceutica - Google Patents

Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina y composicion farmaceutica

Info

Publication number
AR053094A1
AR053094A1 ARP050103959A ARP050103959A AR053094A1 AR 053094 A1 AR053094 A1 AR 053094A1 AR P050103959 A ARP050103959 A AR P050103959A AR P050103959 A ARP050103959 A AR P050103959A AR 053094 A1 AR053094 A1 AR 053094A1
Authority
AR
Argentina
Prior art keywords
substituted
compounds
cholesterol
amino
tetrahydroquinoline
Prior art date
Application number
ARP050103959A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35431286&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR053094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR053094A1 publication Critical patent/AR053094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos 4-amino sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina, composiciones farmacéuticas que contienen tales compuestos. Estos compuestos elevan determinados niveles de lípidos en plasma (incluido lipoproteínas de alta densidad- colesterol) y disminuyen determinados otros niveles de lípidos en el plasma, tales como LDL-colesterol y triglicéridos y, por consiguiente, son utiles para tratar enfermedades que están exacerbadas por bajos niveles de HDL-colesterol y/o altos niveles de LDL-colesterol y triglicéridos, tales como aterosclerosis y enfermedades cardiovasculares en algunos mamíferos, incluidos seres humanos.
ARP050103959A 2004-09-23 2005-09-21 Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina y composicion farmaceutica AR053094A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61286004P 2004-09-23 2004-09-23
US65870405P 2005-03-03 2005-03-03
US11/187,854 US20060063803A1 (en) 2004-09-23 2005-07-25 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds

Publications (1)

Publication Number Publication Date
AR053094A1 true AR053094A1 (es) 2007-04-25

Family

ID=35431286

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103959A AR053094A1 (es) 2004-09-23 2005-09-21 Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina y composicion farmaceutica

Country Status (23)

Country Link
US (2) US20060063803A1 (es)
EP (1) EP1799648A1 (es)
JP (1) JP2008513537A (es)
KR (1) KR100857462B1 (es)
AR (1) AR053094A1 (es)
AU (1) AU2005286186A1 (es)
BR (1) BRPI0515906A (es)
CA (1) CA2581462A1 (es)
CR (1) CR9012A (es)
EA (1) EA200700479A1 (es)
EC (1) ECSP077333A (es)
GT (1) GT200500265A (es)
IL (1) IL181722A0 (es)
MA (1) MA28868B1 (es)
MX (1) MX2007003441A (es)
NI (1) NI200700080A (es)
NL (1) NL1030010C2 (es)
NO (1) NO20071510L (es)
PA (1) PA8646101A1 (es)
PE (1) PE20060820A1 (es)
TN (1) TNSN07100A1 (es)
TW (1) TW200616963A (es)
WO (1) WO2006033002A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511486A (ja) * 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
AU2012202172B2 (en) * 2007-11-05 2013-08-29 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
WO2009071509A1 (en) * 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
TWI627167B (zh) 2011-07-08 2018-06-21 諾華公司 用於高三酸甘油酯個體治療動脈粥狀硬化之方法
PL3464336T3 (pl) 2016-06-01 2022-05-16 Athira Pharma, Inc. Związki

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2882271A (en) * 1959-04-14 Xcixcxh
US3164588A (en) * 1965-01-05 Hjnsoj
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US3009911A (en) * 1961-11-21 Derivatives of j
US3262852A (en) * 1966-07-26 Vasodilator and anti-anginose com- pounds containing methoxy benzyl piperazines and method of using the same
US3108097A (en) * 1963-10-22 Ehnojs
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
US2937169A (en) * 1960-05-17 Toiutf alrtqn of h
US3254076A (en) * 1966-05-31 Sulfamyl hydro
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2357985A (en) * 1940-07-30 1944-09-12 Research Corp Synthesis of hexoestrol
US2500444A (en) * 1944-10-10 1950-03-14 Polaroid Corp Uramidohomomeroquinene
US2796289A (en) * 1954-02-25 1957-06-18 Tocchetto Virgil Dante Adjustable sun visors for motor vehicles
US2769015A (en) * 1954-10-06 1956-10-30 Lab Laroche Navarron Process of preparing 3-methyl-chromone
FR1165845A (fr) * 1955-05-28 1958-10-29 Philips Nv Amines secondaires portant des substituants et leur préparation
BE564542A (es) * 1957-02-05
US3055904A (en) * 1957-11-04 1962-09-25 Geigy Chem Corp New isoindoline derivatives
US2980699A (en) * 1957-12-20 1961-04-18 S B Penick And Company Dihydropyranocoumarin derivatives and process for their production
NL238796A (es) * 1958-05-07
US2970082A (en) * 1958-10-07 1961-01-31 Walker Lab Inc Aluminum nicotinate compositions for hypercholesteremia
US3058882A (en) * 1959-12-28 1962-10-16 Hoechst Ag N'-substituted-3-carboxy-6-halo-sulfanilamide and derivatives thereof
DE1102973B (de) * 1960-03-25 1961-03-23 Bayer Ag Verfahren zur Herstellung von hoch gereinigten Kallikrein-Praeparaten
NL291944A (es) * 1960-05-04
US3081230A (en) * 1960-09-08 1963-03-12 Smith Kline French Lab Diuretic and antihypertensive triaminoarylpteridines
DE1302648B (es) * 1960-09-27
SE300218B (es) * 1960-11-08 1968-04-22 Recip Ab
NL270803A (es) * 1960-11-09
US3255241A (en) * 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
US3072653A (en) * 1961-03-06 1963-01-08 Warner Lamber Pharmaceutical C 5-amino derivatives of 4-thiazolidinones and process therefor
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
FR1312427A (fr) * 1961-04-12 1962-12-21 Science Union Et Compagnie Soc Nouveaux dérivés de la pipérazine et leurs préparations
DE1158966B (de) * 1961-04-29 1963-12-12 Schering Ag Verfahren zur Herstellung von 6-Chlor-1, 2ª‡-methylen-í¸-17ª‡-hydroxyprogesteronestern
GB979994A (en) * 1961-07-28 1965-01-06 May & Baker Ltd Isoindolinone derivatives
AT251777B (de) * 1961-10-05 1967-01-25 Farmaceutici Italia Verfahren zur Herstellung neuer Hendekapeptide
DE1236523C2 (de) * 1962-02-15 1975-06-12 Sanol-Arzneimittel Dr. Schwarz Gmbh, 4019 Monheim Verfahren zur herstellung von basischen phenylaethern und deren salzen
US3262977A (en) * 1962-03-10 1966-07-26 Chinoin Gyogyszer Es Vegyeszet N-aralkyl-1, 1-diphenyl-propylamine derivatives
BE629910A (es) * 1962-03-22
US3188329A (en) * 1962-04-10 1965-06-08 Colgate Palmolive Co Diuretic anils
US3228943A (en) * 1962-06-11 1966-01-11 Lumilysergol derivatives
US3338899A (en) * 1962-07-09 1967-08-29 Aron Samuel 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
NL300886A (es) * 1962-11-23
NL301580A (es) * 1962-12-11
NL142872C (es) * 1963-03-28
US3282936A (en) * 1963-05-01 1966-11-01 Geigy Chem Corp Process for the conversion of cis-2-phenyl-3-methylmorpholine to trans-2-phenyl-3-methylmorpholine
GB1069343A (en) * 1963-09-10 1967-05-17 Ici Ltd Propanolamine derivatives
US3238215A (en) * 1963-10-17 1966-03-01 Sterling Drug Inc 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
NL127996C (es) * 1963-11-19
NL127065C (es) * 1964-04-22
NL137318C (es) * 1964-06-09
US3422107A (en) * 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
GB1078852A (en) * 1964-09-30 1967-08-09 Ici Ltd Alkanolamine derivatives
NL6514807A (es) * 1964-11-18 1966-05-20
GB1084150A (es) * 1965-01-12
US3466325A (en) * 1965-04-30 1969-09-09 Haessle Ab 1-(ortho-alkenyl phenoxy) - 2-hydroxy-3-isopropylaminopropanes and the salts thereof
DE1270544B (de) * 1965-06-19 1968-06-20 Beiersdorf Ag 4-Chlor-5-sulfamylsalicylsaeure-(2', 6'-dimethyl)-anilid und dessen Alkali- oder Ammonium-Salze sowie Verfahren zu deren Herstellung
DE1545575C2 (de) * 1965-12-16 1970-09-10 Asta-Werke Ag, Chemische Fabrik, 4812 Brackwede N, N'-Bis- eckige Klammer auf 3"(3', 4', 5'-trimethoxybenzoyloxy)-propyl eckige Klammer zu -homopiperazin
FR5733M (es) * 1966-09-27 1968-01-22
US3940489A (en) * 1967-02-06 1976-02-24 Boehringer Ingelheim Gmbh Therapeutic compositions and method
US3961071A (en) * 1967-02-06 1976-06-01 Boehringer Ingelheim Gmbh Therapeutic compositions and method
US3563997A (en) * 1967-12-04 1971-02-16 Yoshitomi Pharmaceutical Certain thieno(2,3-c)pyridines
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
GB1203691A (en) * 1968-03-06 1970-09-03 Science Union & Cie New disubstituted n-amino indoline derivatives and process for preparing them
GB1218591A (en) * 1968-04-03 1971-01-06 Delalande Sa Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH510682A (de) * 1968-09-10 1971-07-31 Ciba Geigy Ag Verfahren zur Herstellung von Dihalogentriazinderivaten
DE1815922C3 (de) * 1968-12-20 1979-04-26 Boehringer Mannheim Gmbh, 6800 Mannheim 5-Phenyltetrazol-Derivate
FR8120M (es) * 1968-12-26 1970-08-03
US3836671A (en) * 1969-02-21 1974-09-17 Ici Ltd Alkanolamine derivatives for producing beta-adrenergic blockade
GB1285038A (en) * 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3663570A (en) * 1969-04-28 1972-05-16 Sankyo Co Coumarin derivatives
GB1262785A (en) * 1969-04-29 1972-02-09 Orsymonde Improvements in or relating to phloroglucinol derivatives
CA956632A (en) * 1969-05-16 1974-10-22 Yoshitomi Pharmaceutical Industries Phenoxy-aminopropanol derivatives
US3634583A (en) * 1969-07-24 1972-01-11 Leo Pharm Prod Ltd Pharmaceutical composition for the treatment of oedematous conditions and hypertension
BE757001A (fr) * 1969-10-10 1971-03-16 Cerpha Derives heterocycliques d'acides phenoxy acetique et leur preparation
US3935259A (en) * 1970-01-08 1976-01-27 Ciba-Geigy Corporation New amines and processes for their manufacture
GB1308191A (en) * 1970-04-06 1973-02-21 Science Union & Cie Thiochroman derivatives and a process for preparing them
US3663597A (en) * 1970-05-05 1972-05-16 American Home Prod Process for the purification of cyclandelate
FR2092133B1 (es) * 1970-05-06 1974-03-22 Orsymonde
US3669968A (en) * 1970-05-21 1972-06-13 Pfizer Trialkoxy quinazolines
DE2130393C3 (de) * 1970-06-22 1981-02-26 E.R. Squibb & Sons Inc., New York, N.Y. (V.St.A.) 6,7-Dihydroxy -5,6,7,8-tetrahydronaphthyloxyaminopropanole und ihre Salze mit Säuren sowie ihre Verwendung bei der Bekämpfung von Herzerkrankungen
FR2092895B1 (es) * 1970-06-29 1973-07-13 Lafon Victor
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
ZA732937B (en) * 1972-05-05 1974-03-27 Maggioni & C Spa Non mercurial diuretics
GB1435139A (en) * 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
US3980679A (en) * 1973-01-29 1976-09-14 Hoechst Aktiengesellschaft Process for the manufacture of glycidyl ethers of monohydric or polyhydric phenols, having improved properties
US4521607A (en) * 1981-02-27 1985-06-04 Takeda Chemical Industries, Ltd. Chromanyl glycines
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US20050228016A1 (en) * 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
MXPA05003456A (es) * 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
JP2006511486A (ja) * 2002-10-21 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｃｒｔｈ２拮抗剤としてのテトラヒドロキノリン誘導体
WO2005007094A2 (en) * 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения

Also Published As

Publication number Publication date
NL1030010C2 (nl) 2006-11-06
PE20060820A1 (es) 2006-09-06
NL1030010A1 (nl) 2006-03-27
EA200700479A1 (ru) 2007-10-26
IL181722A0 (en) 2007-07-04
CR9012A (es) 2007-04-24
MX2007003441A (es) 2007-05-23
KR100857462B1 (ko) 2008-09-08
PA8646101A1 (es) 2006-06-02
NO20071510L (no) 2007-06-11
WO2006033002A1 (en) 2006-03-30
MA28868B1 (fr) 2007-09-03
US20060247272A1 (en) 2006-11-02
KR20070045346A (ko) 2007-05-02
BRPI0515906A (pt) 2008-08-12
NI200700080A (es) 2008-03-07
ECSP077333A (es) 2007-04-26
GT200500265A (es) 2006-04-21
TW200616963A (en) 2006-06-01
JP2008513537A (ja) 2008-05-01
AU2005286186A1 (en) 2006-03-30
US20060063803A1 (en) 2006-03-23
CA2581462A1 (en) 2006-03-30
EP1799648A1 (en) 2007-06-27
TNSN07100A1 (fr) 2008-06-02

Similar Documents

Publication Publication Date Title
AR053094A1 (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina y composicion farmaceutica
BRPI0518476A2 (pt) compostos e derivados de dibenzil amina
ECSP056040A (es) 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD
DOP2007000044A (es) Compuestos y derivados de dibencilamina
RS20050395A (en) Ppar activators
MY121405A (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
MX2008000178A (es) Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
UA83202C2 (ru) Фенилзамещенные пиперидины для использования в качестве активаторов рапп
MY130670A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
CR10937A (es) Inhibidores de cinasa mapk/erk
TW200616964A (en) Quinoline compounds
ECSP088729A (es) Compuestos y derivados de dibencilamina
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
DOP2005000182A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3-tetrahidroquinolina
UY29123A1 (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
ECSP088730A (es) Derivados de dibencilamina como inhibidores de cetp
DOP2005000179A (es) Compuesto de quinolina
DOP2004000863A (es) Compuestos de quinolina y quinoxalina
CU20080164A7 (es) Compuestos y derivados de dibencilamina
DOP2005000238A (es) Compuestos y derivados de dibencil amina
UY27168A1 (es) Agonistas de ppar
UY27158A1 (es) Compuestos de ppar
DOP2002000327A (es) Agonistas de ppar
WO2012078674A8 (en) Substituted indole/indazole-pyrimidinyl compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal